Implementing this strategy resulted in an average reduction in CD4 count of 16, a 10% increase in the number of individuals reporting adherence of 95% or higher and a significant reduction in depression indicated by the PHQ score −12.8 (−14.2 to –11.3).23 The gene discussed is CD4; the disease is depressive symptom measurement.